ClinicalTrials.gov
ClinicalTrials.gov Menu

The ADHERENCE Index - the Indicator of Effective Coping With the Requirements of the Disease of Children and Adolescents With Type 1 Diabetes (ADHERENCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01580462
Recruitment Status : Unknown
Verified April 2012 by Institution of Mother and Child, Warsaw, Poland.
Recruitment status was:  Recruiting
First Posted : April 19, 2012
Last Update Posted : April 19, 2012
Sponsor:
Information provided by (Responsible Party):
Institution of Mother and Child, Warsaw, Poland

Brief Summary:
The aim of the research is to develop a mathematical model called ADHERENCE index, and to evaluate its effectiveness.

Condition or disease Intervention/treatment
Type 1 Diabetes Other: Observational study

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 200 participants
Time Perspective: Prospective
Official Title: The ADHERENCE Index - the Indicator of Effective Coping With the Requirements of the Disease of Children and Adolescents With Type 1 Diabetes. Prospective Study
Study Start Date : April 2012
Estimated Primary Completion Date : June 2012
Estimated Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Group/Cohort Intervention/treatment
Children and Adolescent with type 1 diabetes on CSII Other: Observational study

Study plan - data collecting:

Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded.






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Participants will be recruited from the Outpatient Diabetes Clinic in the Institute of Mother and Child. Patient should be treated by intensive insulinotherapy using Continous Subcutaneus Infusion Set (CSII). Number of participants: 200.
Criteria

Inclusion Criteria:

  • type 1 diabetes for min. 1 year
  • CSII
  • ability to come for one additional visit in outpatient diabetes clinic
  • using glucometers

Exclusion Criteria:

  • no possibility to download data from patient's glucometer and insulin pump

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01580462


Contacts
Contact: Katarzyna A Gajewska, MSc 48223277105 katarzyna.gajewska@imid.med.pl

Locations
Poland
Outpatient Diabetes Clinic of the Institute of Mother and Child Recruiting
Warsaw, Mazowieckie, Poland, 01-211
Principal Investigator: Katarzyna A Gajewska, MSc         
Sponsors and Collaborators
Institution of Mother and Child, Warsaw, Poland

Responsible Party: Institution of Mother and Child, Warsaw, Poland
ClinicalTrials.gov Identifier: NCT01580462     History of Changes
Other Study ID Numbers: OPK 510-13-55
First Posted: April 19, 2012    Key Record Dates
Last Update Posted: April 19, 2012
Last Verified: April 2012

Keywords provided by Institution of Mother and Child, Warsaw, Poland:
continuous subcutaneous insulin infusion (CSII)
children
adolescent

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases